Development of Indicators to Assess Quality of Care for Prostate Cancer

Nag, N; Millar, J; Davis, ID; Costello, S; Duthie, JB; Mark, S; Delprado, W; Smith, D; Pryor, D; Galvin, D; Sullivan, F; Murphy, Á; Roder, D; Elsaleh, H; Currow, D; White, C; Skala, M; Moretti, KL; Walker, T; De Ieso, P; Brooks, A; Heathcote, P; Frydenberg, M; Thavaseelan, J; Evans, SM

Development of Indicators to Assess Quality of Care for Prostate Cancer

Nag, N Millar, J Davis, ID Costello, S Duthie, JB Mark, S Delprado, W Smith, D Pryor, D Galvin, D Sullivan, F Murphy, Á Roder, D Elsaleh, H Currow, D

White, C Skala, M Moretti, KL Walker, T De Ieso, P Brooks, A Heathcote, P Frydenberg, M Thavaseelan, J Evans, SM

Permalink

Publisher:: ELSEVIER
Publication Type:: Journal Article
Citation:: European urology focus, 2018, 4, (1), pp. 57-63
Issue Date:: 2018

Closed Access

	Filename	Description	Size
	1-s2.0-S2405456916000183-main.pdf	Published version	210.18 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Nag, N
dc.contributor.author	Millar, J
dc.contributor.author	Davis, ID
dc.contributor.author	Costello, S
dc.contributor.author	Duthie, JB
dc.contributor.author	Mark, S
dc.contributor.author	Delprado, W
dc.contributor.author	Smith, D
dc.contributor.author	Pryor, D
dc.contributor.author	Galvin, D
dc.contributor.author	Sullivan, F
dc.contributor.author	Murphy, Á
dc.contributor.author	Roder, D
dc.contributor.author	Elsaleh, H
dc.contributor.author	Currow, D https://orcid.org/0000-0003-1988-1250
dc.contributor.author	White, C
dc.contributor.author	Skala, M
dc.contributor.author	Moretti, KL
dc.contributor.author	Walker, T
dc.contributor.author	De Ieso, P
dc.contributor.author	Brooks, A
dc.contributor.author	Heathcote, P
dc.contributor.author	Frydenberg, M
dc.contributor.author	Thavaseelan, J
dc.contributor.author	Evans, SM
dc.date.accessioned	2022-04-19T03:25:13Z
dc.date.available	2016-01-25
dc.date.available	2022-04-19T03:25:13Z
dc.date.issued	2018
dc.identifier.citation	European urology focus, 2018, 4, (1), pp. 57-63
dc.identifier.issn	2405-4569
dc.identifier.issn	2405-4569
dc.identifier.uri	http://hdl.handle.net/10453/156419
dc.description.abstract	BACKGROUND: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care. OBJECTIVE: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panellists were asked to rate each proposed indicator on a Likert scale of 1-9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry-Australia and New Zealand (PCOR-ANZ). RESULTS AND LIMITATIONS: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ. CONCLUSIONS: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes. PATIENT SUMMARY: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ELSEVIER
dc.relation.ispartof	European urology focus
dc.relation.isbasedon	10.1016/j.euf.2016.01.016
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences
dc.subject.mesh	Benchmarking
dc.subject.mesh	Delivery of Health Care
dc.subject.mesh	Delphi Technique
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Outcome Assessment, Health Care
dc.subject.mesh	Patient Outcome Assessment
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Quality Indicators, Health Care
dc.subject.mesh	Quality of Health Care
dc.subject.mesh	Registries
dc.subject.mesh	Risk Adjustment
dc.subject.mesh	Humans
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Registries
dc.subject.mesh	Delphi Technique
dc.subject.mesh	Benchmarking
dc.subject.mesh	Risk Adjustment
dc.subject.mesh	Delivery of Health Care
dc.subject.mesh	Quality of Health Care
dc.subject.mesh	Quality Indicators, Health Care
dc.subject.mesh	Male
dc.subject.mesh	Patient Outcome Assessment
dc.subject.mesh	Outcome Assessment, Health Care
dc.title	Development of Indicators to Assess Quality of Care for Prostate Cancer
dc.type	Journal Article
utslib.citation.volume	4
utslib.location.activity	Netherlands
utslib.for	1110 Nursing
utslib.for	1103 Clinical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-04-19T03:25:12Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	4
utslib.citation.issue	1

Abstract:

BACKGROUND: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care. OBJECTIVE: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panellists were asked to rate each proposed indicator on a Likert scale of 1-9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry-Australia and New Zealand (PCOR-ANZ). RESULTS AND LIMITATIONS: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ. CONCLUSIONS: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes. PATIENT SUMMARY: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/156419